Anise T Wheeler, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 1 carrier
- Office
- 1
- Since medical school
- 27 years
- Graduated 1999
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Anise T Wheeler’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C11081 · Deceased
Licence status: Deceased · since 1948 · Northwestern University Medical School.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$48,133
Medicare paid this office $48,133 for 192 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 144 | $22,790 | $94 |
| Long return visit (40+ min) | 94 | $19,496 | $133 |
| Short return visit (20+ min) | 30 | $2,238 | $57 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 92 | $1,740 | $13 |
Who their Medicare patients are
192 Original Medicare patients in 2024. Average age 73 · Under 65 16% · 85 and older 11% · Women 71% · Also on Medicaid 25% · Health risk score 1.57. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 71% · Depression 37% · Diabetes 30% · Chronic kidney disease 28% · Coronary heart disease 26% · Atrial fibrillation 19% · Cancer 17% · COPD 14% · Heart failure 11% · Stroke 7%.
The office billed $297,515, Medicare allowed $62,895 and paid $48,133; for 590 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 192 | 590 | 73 | 1.57 | $297,515 | $48,133 |
| 2023 | 121 | 361 | 71 | 1.47 | $173,016 | $23,556 |
| 2022 | 142 | 239 | 69 | 1.40 | $76,186 | $19,306 |
| 2021 | 42 | 159 | 65 | 0.97 | $24,983 | $12,026 |
| 2020 | 20 | 45 | 64 | 1.25 | $7,768 | $3,116 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 93 | $12,610 | $68 |
| Short return visit (20+ min) | 60 | $4,536 | $42 |
| Long return visit (40+ min) | 37 | $4,366 | $97 |
2022: 5 services
| Return visit (30+ min) | 60 | $6,304 | $75 |
| Long return visit (40+ min) | 30 | $3,594 | $109 |
| Return visit (30+ min) | 31 | $3,274 | $57 |
| New patient visit (60+ min) | 22 | $3,100 | $141 |
| Short return visit (20+ min) | 16 | $853 | $50 |
2021: 3 services
| Return visit (30+ min) | 35 | $7,992 | $67 |
| Psychiatric diagnostic evaluation with medical services | 26 | $2,919 | $112 |
| Psychiatric diagnostic evaluation | 11 | $898 | $82 |
2020: 2 services
| Psychiatric diagnostic evaluation | 12 | $1,315 | $88 |
| Return visit (30+ min) | 13 | $1,161 | $53 |
Drugs they prescribed that Part D paid
$51,147
Pharmacies billed $51,147 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 18% of their Part D prescriptions (126 of 690) in 2024. A higher opioid share than 9 in 10 peers; the typical nurse practitioner clinician is at 0%. Long-acting opioids: 28% of their opioid prescriptions.
649 generic and 41 brand-name prescriptions · $51,147 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Aimovig | Migraine | 12 | $8,553 | $713 |
| Buprenorphine | None | 30 | $2,554 | $85 |
| Lidocaine | None | 31 | $2,135 | $69 |
| Pregabalin | None | 130 | $2,105 | $16 |
| Gabapentin | None | 113 | $1,975 | $17 |
See all 15 drugs
| Aimovig | Migraine | 12 | $8,553 | $713 |
| Buprenorphine | None | 30 | $2,554 | $85 |
| Lidocaine | None | 31 | $2,135 | $69 |
| Pregabalin | None | 130 | $2,105 | $16 |
| Gabapentin | None | 113 | $1,975 | $17 |
| Tizanidine | None | 19 | $1,389 | $73 |
| Duloxetine | None | 51 | $1,363 | $27 |
| Hydrocodone-Acetaminophen | None | 58 | $1,198 | $21 |
| Celecoxib | None | 32 | $1,185 | $37 |
| Mirtazapine | None | 12 | $572 | $48 |
| Baclofen | None | 22 | $473 | $21 |
| Diclofenac | None | 16 | $338 | $21 |
| Nabumetone | None | 15 | $224 | $15 |
| Cyclobenzaprine | None | 16 | $181 | $11 |
| Acetaminophen-Codeine | None | 14 | $120 | $9 |
Year by year
| 2024 | 690 | 134 | 18% (126) | 6% | $51,147 |
| 2023 | 558 | 97 | 21% (115) | 4% | $45,975 |
| 2022 | 807 | 116 | 8% (67) | 3% | $57,618 |
| 2021 | 1,359 | 87 | 0% (0) | 6% | $193,896 |
| 2020 | 611 | 42 | 0% (0) | 13% | $191,684 |
| 2019 | 464 | 23 | 0% (0) | 15% | $161,638 |
| 2018 | 635 | 26 | 0% (0) | 11% | $119,944 |
| 2017 | 141 | 14 | 0% (0) | None | $7,881 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Buprenorphine | 25 | $7,092 | $284 |
| Pregabalin | 109 | $5,774 | $53 |
| Hydrocodone-Acetaminophen | 62 | $2,201 | $36 |
| Gabapentin | 84 | $1,574 | $19 |
| Mirtazapine | 21 | $1,253 | $60 |
| Lidocaine | 21 | $1,078 | $51 |
| Duloxetine | 28 | $1,060 | $38 |
| Diclofenac | 26 | $749 | $29 |
| Buprenorphine | 11 | $741 | $67 |
| Celecoxib | 20 | $598 | $30 |
| Baclofen | 20 | $398 | $20 |
| Topiramate | 15 | $177 | $12 |
| Acetaminophen-Codeine | 13 | $108 | $8 |
2022: 25 drugs
| Aripiprazole | 44 | $10,375 | $236 |
| Buprenorphine | 11 | $3,572 | $325 |
| Duloxetine | 43 | $2,605 | $61 |
| Olanzapine | 26 | $1,792 | $69 |
| Pregabalin | 32 | $1,742 | $54 |
| Buspirone | 89 | $1,427 | $16 |
| Hydrocodone-Acetaminophen | 41 | $1,256 | $31 |
| Quetiapine | 20 | $737 | $37 |
| Bupropion Xl | 14 | $699 | $50 |
| Benztropine Mesylate | 32 | $526 | $16 |
| Celecoxib | 11 | $513 | $47 |
| Gabapentin | 30 | $493 | $16 |
| Diclofenac | 13 | $424 | $33 |
| Prazosin | 19 | $351 | $18 |
| Fluphenazine Decanoate | 12 | $344 | $29 |
| Lamotrigine | 31 | $285 | $9 |
| Risperidone | 14 | $259 | $19 |
| Venlafaxine Hcl Er | 25 | $233 | $9 |
| Sertraline | 38 | $225 | $6 |
| Paroxetine | 18 | $192 | $11 |
| Mirtazapine | 13 | $133 | $10 |
| Trazodone | 13 | $115 | $9 |
| Fluoxetine | 12 | $77 | $6 |
| Escitalopram | 15 | $76 | $5 |
| Lorazepam | 16 | $74 | $5 |
2021: 35 drugs
| Invega Sustenna | 21 | $55,524 | $2,644 |
| Abilify Maintena | 15 | $36,308 | $2,421 |
| Vraylar | 13 | $16,013 | $1,232 |
| Aripiprazole | 102 | $8,962 | $88 |
| Buspirone | 160 | $2,533 | $16 |
| Asenapine Maleate | 11 | $2,505 | $228 |
| Olanzapine | 56 | $1,561 | $28 |
| Fluphenazine Decanoate | 26 | $846 | $33 |
| Benztropine Mesylate | 90 | $824 | $9 |
| Quetiapine | 37 | $717 | $19 |
| Duloxetine | 32 | $716 | $22 |
| Divalproex Sodium Er | 23 | $665 | $29 |
| Bupropion Xl | 25 | $634 | $25 |
| Venlafaxine Hcl Er | 37 | $526 | $14 |
| Prazosin | 24 | $522 | $22 |
| Guanfacine Hcl Er | 22 | $515 | $23 |
| Sertraline | 68 | $502 | $7 |
| Divalproex | 15 | $470 | $31 |
| Methylphenidate Er | 12 | $466 | $39 |
| Trazodone | 46 | $395 | $9 |
| Risperidone | 47 | $331 | $7 |
| Hydroxyzine Pamoate | 39 | $317 | $8 |
| Lorazepam | 55 | $276 | $5 |
| Lamotrigine | 41 | $276 | $7 |
| Escitalopram | 31 | $208 | $7 |
| Gabapentin | 35 | $186 | $5 |
| Fluoxetine | 24 | $175 | $7 |
| Propranolol | 16 | $154 | $10 |
| Paroxetine | 16 | $135 | $8 |
| Mirtazapine | 11 | $107 | $10 |
| Alprazolam | 15 | $106 | $7 |
| Citalopram Hbr | 16 | $101 | $6 |
| Zolpidem | 19 | $84 | $4 |
| Hydroxyzine | 11 | $66 | $6 |
| Topiramate | 15 | $44 | $3 |
2020: 22 drugs
| Abilify Maintena | 29 | $68,486 | $2,362 |
| Invega Sustenna | 14 | $37,423 | $2,673 |
| Aripiprazole | 26 | $3,623 | $139 |
| Divalproex Sodium Er | 23 | $1,130 | $49 |
| Lamotrigine Er | 13 | $794 | $61 |
| Olanzapine | 19 | $456 | $24 |
| Fluphenazine Decanoate | 16 | $439 | $27 |
| Sertraline | 41 | $368 | $9 |
| Hydroxyzine Pamoate | 32 | $356 | $11 |
| Benztropine Mesylate | 54 | $346 | $6 |
| Prazosin | 18 | $242 | $13 |
| Risperidone | 24 | $203 | $8 |
| Gabapentin | 29 | $201 | $7 |
| Quetiapine | 18 | $194 | $11 |
| Trazodone | 27 | $172 | $6 |
| Duloxetine | 17 | $144 | $8 |
| Propranolol | 14 | $141 | $10 |
| Lamotrigine | 23 | $99 | $4 |
| Citalopram Hbr | 21 | $92 | $4 |
| Fluoxetine | 13 | $71 | $5 |
| Buspirone | 17 | $69 | $4 |
| Escitalopram | 16 | $51 | $3 |
2019: 15 drugs
| Abilify Maintena | 25 | $58,002 | $2,320 |
| Latuda | 23 | $30,177 | $1,312 |
| Aripiprazole | 20 | $5,509 | $275 |
| Duloxetine | 14 | $2,110 | $151 |
| Benztropine Mesylate | 49 | $289 | $6 |
| Trazodone | 39 | $287 | $7 |
| Hydroxyzine Pamoate | 23 | $147 | $6 |
| Sertraline | 33 | $135 | $4 |
| Risperidone | 16 | $126 | $8 |
| Propranolol | 11 | $114 | $10 |
| Gabapentin | 17 | $99 | $6 |
| Quetiapine | 15 | $88 | $6 |
| Citalopram Hbr | 20 | $73 | $4 |
| Lamotrigine | 17 | $46 | $3 |
| Clonazepam | 27 | $25 | $1 |
2018: 17 drugs
| Abilify Maintena | 19 | $42,852 | $2,255 |
| Invega | 26 | $11,209 | $431 |
| Aripiprazole | 32 | $3,537 | $111 |
| Divalproex Sodium Er | 22 | $696 | $32 |
| Bupropion Xl | 27 | $400 | $15 |
| Hydroxyzine Pamoate | 70 | $333 | $5 |
| Benztropine Mesylate | 86 | $310 | $4 |
| Trazodone | 66 | $308 | $5 |
| Quetiapine | 27 | $136 | $5 |
| Risperidone | 39 | $123 | $3 |
| Fluoxetine | 14 | $101 | $7 |
| Propranolol | 15 | $95 | $6 |
| Paroxetine | 13 | $83 | $6 |
| Lamotrigine | 27 | $63 | $2 |
| Citalopram Hbr | 21 | $62 | $3 |
| Clonazepam | 14 | $39 | $3 |
| Sertraline | 15 | $34 | $2 |
2017: 4 drugs
| Trazodone | 24 | $129 | $5 |
| Risperidone | 13 | $95 | $7 |
| Propranolol | 11 | $74 | $7 |
| Citalopram Hbr | 11 | $9 | $1 |
Money from drug and device companies
$225 in 2023
A payment is not proof that care is biased.
| Impel Pharmaceuticals | Trudhesa | $110 | 1 payment
|
| Abbvie | Qulipta | $69 | 1 payment
|
| Averitas Pharma | Qutenza | $46 | 1 payment
|
See all 3 published payments
| Abbvie | Meals · 2023-09-06 | Qulipta | $69 |
| Averitas Pharma | Meals · 2023-09-05 | Qutenza | $46 |
| Impel Pharmaceuticals | Meals · 2023-02-08 | Trudhesa | $110 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720191885
- Licence
- CA 11081, CA RN514339California C11081: Deceased
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-15
- NPI last updated
- 2025-12-31
- NPI record certified
- 2025-12-31
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.